First Tracks Biotherapeutics, Inc. (TRAX)
44.46
-0.65
(-1.44%)
USD |
NASDAQ |
Aug 26, 10:56
First Tracks Biotherapeutics Enterprise Value : 1.433B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 1.433B |
| August 24, 2026 | 1.368B |
| August 21, 2026 | 1.362B |
| August 20, 2026 | 1.319B |
| August 19, 2026 | 1.447B |
| August 18, 2026 | 1.389B |
| August 17, 2026 | 1.379B |
| August 14, 2026 | 1.395B |
| August 13, 2026 | 1.395B |
| August 12, 2026 | 1.469B |
| August 11, 2026 | 1.491B |
| August 10, 2026 | 1.532B |
| August 07, 2026 | 1.441B |
| August 06, 2026 | 1.440B |
| August 05, 2026 | 1.498B |
| August 04, 2026 | 1.465B |
| August 03, 2026 | 1.470B |
| July 31, 2026 | 1.395B |
| July 30, 2026 | 1.527B |
| July 29, 2026 | 1.318B |
| July 28, 2026 | 1.317B |
| July 27, 2026 | 1.324B |
| July 24, 2026 | 1.093B |
| July 23, 2026 | 1.168B |
| July 22, 2026 | 1.187B |
| Date | Value |
|---|---|
| July 21, 2026 | 1.159B |
| July 20, 2026 | 1.141B |
| July 17, 2026 | 1.129B |
| July 16, 2026 | 1.118B |
| July 15, 2026 | 1.115B |
| July 14, 2026 | 1.053B |
| July 13, 2026 | 1.075B |
| July 10, 2026 | 1.119B |
| July 09, 2026 | 982.97M |
| July 08, 2026 | 571.38M |
| July 07, 2026 | 536.34M |
| July 06, 2026 | 545.54M |
| July 02, 2026 | 519.36M |
| July 01, 2026 | 494.23M |
| June 30, 2026 | 548.38M |
| June 29, 2026 | 307.06M |
| June 26, 2026 | 272.87M |
| June 25, 2026 | 284.73M |
| June 24, 2026 | 295.90M |
| June 23, 2026 | 333.93M |
| June 22, 2026 | 352.77M |
| June 18, 2026 | 321.37M |
| June 17, 2026 | 347.54M |
| June 16, 2026 | 311.60M |
| June 15, 2026 | 337.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Forte Biosciences, Inc. | 1.378B |
| ACADIA Pharmaceuticals, Inc. | 4.379B |
| Agenus, Inc. | 620.93M |
| Alnylam Pharmaceuticals, Inc. | 31.79B |
| Amgen, Inc. | 282.39B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.37M |
| Total Expenses (Quarterly) | 33.37M |
| EPS Diluted (Quarterly) | -0.943 |
| Earnings Yield | -11.11% |
| Normalized Earnings Yield | -11.12 |